A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement-Reference-Cited by-同舟云学术

A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement

Published:1991 Issue:6 Volume:28 Page:465-469
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother. Pharmacol.

Author:

Jakobsen Preben,Bastholt Lars,Dalmark Mads,Pfeiffer Per,Petersen Dorthe,Gjedde Susanne B.,Sandberg Erik,Rose Carsten,Nielsen Ole S.,Mouridsen Henning T.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/BF00685824.pdf

Reference12 articles.

1. Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule JA (1989) Pharmacokinetics and pharmacodynamics of long term continuous-infusion. Clin Pharmacol Ther 45: 340

2. Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Panutti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol 21: 221

3. Deesen PE, Leyland-Jones B (1984) Sensitive and specific determination of the new anthracycline analog 4?-epirubicin and its metabolites by high pressure liquid chromatography. Drug Metab Dispos 12: 9

4. Eichholtz-Wirth H (1980) Dependence of the cytostatic effect of Adriamycin on drug concentration and exposure time in vitro. Br J Cancer 41: 886

5. Eksborg S (1990) Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). Acta Oncol 29: 239

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial;BMJ Open;2024-04

2. A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer;Clinical Breast Cancer;2016-04

3. Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment;European Journal of Clinical Pharmacology;2016-02-26

4. Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia;European Journal of Clinical Pharmacology;2015-10-27

5. Dose Schedule Optimization and the Pharmacokinetic Driver of Neutropenia;PLoS ONE;2014-10-31